biotherapeutics_for_everybody_1 biotherapeutics_for_everybody_3 biotherapeutics_for_everybody_2
Icone heart

We make biotherapeutics more available & sustainable For everybody

"Progress is only worthwhile if it is shared by all”
Aristotle

Discover now
Icone ADN
Icone glow
Today's Challenge

Global unmet medical needs today

underline

  • Global issue

    Both Western and Emerging economies face major issues to produce biopharmaceuticals. . The Production volumes and costs of current generation of biopharmaceuticals deprives vast populations around the world access to life-saving medicines.

    The acute needs for monoclonal antibodies is also emphasized by the WHO.

  • Availability issue

    World-wide Volume of biopharmaceuticals is limited today to a few % of global pharmaceuticals, despite the fact that targeted therapies are much safer and much more effective.

    The Availability of Monoclonal Antibodies, for example, is dramatically lower than needs in Western Countries, particularly in the event of Pandemics and even more so in Emerging Countries where there are almost no Production Units.

  • Accessibility issue

    The low productivity of current biopharmaceutical production technologies implies enormous investment costs* for low volumes**, resulting in very high treatment costs for the patient.

    The Accessibility of these essential
    medicines is therefore mainly limited for wealthy people and/or people benefiting from health insurance systems in Western Countries.

* 250 to 500 million dollars for a production unit / ** A few hundred kg
Image planete
Icone solutions Our solution for global health
Icone glow
Ready to change?
What we propose

We promote what nature gives us

We have been working to change the production’s paradigm and we are ready today to propose to countries, governments and main industry’s players our new generation of Biopharmaceutical.

Our solution
What is it about?

More available, affordable, sustainable

We strongly believe we can make a significant contribution to the world's enormous and urgent unmet needs, including pandemics, while meeting sustainable development goals.

At Biosourcing, we have developed a proprietary technological platform to express proteins of interest in the milk of dedicated animals : We shift from steel bioreactors to natural bioreactors by exploiting state-of-the-art techniques.

Our unique expertise

The best natural bioreactor of protein

Thanks to Unique Expertise in combining Breakthrough technologies: CRISPR-Cas9, the gene-editing technology, the Nuclear Transfer and the reproductive technology, we industrialize the best natural bioreactor of protein : Milk of specialized goat.

Image scientific
Icone eye We go from steel-tank to ‘bio-tank’
Icone glow
  • Milk? Icone arrow

    In a practical way, we apply gene therapy techniques followed by in vitro fertilization techniques to obtain goats producing in their milk large quantities of biopharmaceuticals such as fully human monoclonal antibodies.

  • From the milk thus produced in large quantities, pharmaceutical grade purification processes make it possible to obtain high quality biopharmaceuticals at a production cost and carbon footprint drastically lower than current production techniques.

added value icone Added value
Added value

The tremendous advantages of our breakthrough platform

  • icone

    Drastic reduction of capital requirements and production costs, especially for volumes larger than a ton.

  • Icone flacon

    Better Biopharmaceuticals (BioBodies) due to improved glycosylation.

  • Icone mouth

    High Adaptability and scalability to evolving needs.

  • Icone heart

    Ease of industrialization, reproducibility, and of re-localization of the goat farms.

Icone personnes

SDGs:
Good Health and Well Being, Reduction of the carbon footprint, contribution to sustainable development.

  • Icone eyes red

    Executive Management team

    We are a team of 15 scientists, with International expertise in their field.

    Our laboratories are based in Liège, Belgium, since 2014. Our business model is based on co-development and co-ownership of results, to allow early income and long-term revenues (royalties).

    Get in touch
  • bertrand merot

    Bertrand Mérot

    Founder & CEO
    With a doctorate in genetics and an MBA, Dr. Mérot began his career in academic research before joi ...
    With a doctorate in genetics and an MBA, Dr. Mérot began his career in academic research before joining major international groups such as Limagrain Group and LFB Biotechnology, where he held various positions including R&D Director, General Manager of the healthcare branch, Vice President, Chairman and CEO. Dr Mérot has also created and/or developed several biotechnology companies such as Meristem Therapeutics, OncoDesign, GTC Biotherapeutics, in Europe and the United States. With his research teams, Dr Mérot has been behind several world firsts, resulting in patents and publications including in the journal Nature. Dr Mérot was also a member of the Board of Directors of France Biotech and an expert to the European Commission.
  • Taveres Kaio

    Pr. Kaio Tavares

    Research Director
    Dr. Tavares holds a PhD in Biotechnology (UNIFOR/UECE), complemented by a Sandwich PhD at The Roslin ...
    Dr. Tavares holds a PhD in Biotechnology (UNIFOR/UECE), complemented by a Sandwich PhD at The Roslin Institute (University of Edinburgh). With over 15 years of expertise in genetic engineering and recombinant protein manufacturing, Dr. Tavares specializes in producing biotherapeutics in the goat milk. He previously served as a Professor and Principal Investigator at the University of Fortaleza and was a co-founder of a biopharmaceutical startup (Fortgen Technologies), where he spearheaded the design and management of multiple projects.
  • Alain Vanderplasschen

    Pr. Alain Vanderplasschen

    CSO
    Two PhDs, one in Veterinary Medicine at University of Liège (1995) and one in Medicine at Oxford Un ...
    Two PhDs, one in Veterinary Medicine at University of Liège (1995) and one in Medicine at Oxford University (1998). He is Professor of Immunology Vaccinology at the faculty of Veterinary Medicine of the University of Liège where he worked as Research Director of the « FNRS ». He is the laureate of several scientific awards including the "GSK vaccines prize" and two "Francaui chairs".
  • Mathieu delvaux

    Mathieux Delveaux

    CFO
    Mathieu is a finance manager with >15 years of experience in audit, controlling, business developmen ...
    Mathieu is a finance manager with >15 years of experience in audit, controlling, business development and financing. Graduated from Solvay Business School. he started his career as financial auditor (Deloitte) and then, spent most of his career in the pharma sector (IBA, Cisbio) and in the financing of SME's.
  • Brigitte gerard

    Brigitte Genard

    COO
    Pharmacist and MBA has extensive high-level management experience in the biopharmaceutical sector.Sh ...
    Pharmacist and MBA has extensive high-level management experience in the biopharmaceutical sector.She has held positions in different organizations: Large companies like GSK or UCB but also CDMOs and startups.Brigitte managed different departments and projects in quality, manufacturing, regulatory affairs and product development.
icon

Proposing a sustainable, affordable and accessible alternative to the pharmaceutical production platform of today.

We intent to do so by scaling-up the unprecedented efficiency of its validated BioMilk Platform to produce Biopharmaceuticals.